{"id":46679,"date":"2022-07-28T14:01:44","date_gmt":"2022-07-28T12:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/"},"modified":"2022-07-28T14:01:44","modified_gmt":"2022-07-28T12:01:44","slug":"silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/","title":{"rendered":"Silversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund"},"content":{"rendered":"
\n

BOSTON–(BUSINESS WIRE)–Silversmith Capital Partners<\/a> (\u201cSilversmith\u201d) today announced the first and final close of its fourth fund, Silversmith Capital Partners IV (\u201cFund IV\u201d). Launched in May 2022, Fund IV was significantly oversubscribed and closed at its target and hard cap of $1.25 billion. In addition to the $1.25 billion from limited partners, the Silversmith team will contribute $90 million to Fund IV. Fund IV is the firm\u2019s largest to date and brings total capital raised to more than $3.3 billion since its founding in 2015. Consistent with the strategy of its predecessor funds, Fund IV will focus on partnering with and supporting the best entrepreneurs leading growing, profitable technology and healthcare companies.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nSilversmith received strong support from its existing investor base of leading endowments, foundations, fund-of-funds and pension funds, while also adding a small number of new institutional investors. In addition, 50 CEOs, founders, and industry executives invested in Fund IV. The firm closed its first fund of $460 million in 2015, its second fund of $670 million in 2018, and its third fund of $880 million in 2020.\n<\/p>\n

\n\u201cOur investment strategy was built on four bedrock tenets that have not changed over the past seven years \u2013 invest in markets we know, invest in companies as they inflect, invest in companies that are capital efficient, and partner with truly exceptional entrepreneurs,\u201d said Jim Quagliaroli, Managing Partner of Silversmith. \u201cThe steadfast support we received from our investors speaks volumes to how much the limited partner community values a disciplined approach. We are grateful for the trust and confidence our investors have in Silversmith and look forward to continuing to execute on our investment strategy.\u201d\n<\/p>\n

\nSince its founding, Silversmith has invested in 41 growth-stage companies, had 16 full or partial realizations representing $1.7 billion in cash proceeds, expanded its team to more than 35 people, and grown its Senior Advisor network to 10 senior executives from leading technology and healthcare companies. Consistent with previous Silversmith funds, Fund IV will make minority and majority investments of $20 million to $125 million in SaaS & Information Services and Healthcare IT & Services companies that are primarily founder-led, profitable and have not previously raised institutional capital.\n<\/p>\n

\n\u201cWe started Silversmith with the mission to build a firm with a collaborative, team-based culture that was focused on partnering with and supporting the best entrepreneurs,\u201d said Jeff Crisan, Managing Partner of Silversmith. \u201cThe success we have achieved as a firm is a testament to the dedication of our team and the strength of the entrepreneurs who work tirelessly to build great businesses.\u201d\n<\/p>\n

\nKirkland & Ellis provided fund formation counsel.\n<\/p>\n

\nAbout Silversmith Capital Partners<\/b>\n<\/p>\n

\nFounded in 2015, Silversmith Capital Partners is a Boston-based growth equity firm with $3.3 billion of capital under management. Silversmith\u2019s mission is to partner with and support the best entrepreneurs in growing, profitable technology and healthcare companies. Representative investments include ActiveCampaign, Appfire, DistroKid, impact.com, Iodine Software, LifeStance Health, and Webflow. For more information about Silversmith, please visit www.silversmith.com<\/a> or follow the firm on LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPress:
\n
Kate Castle
\n
Chief Marketing Officer
\n
Silversmith Capital Partners
\n
P: 617.670.4345
\n
kate@silversmith.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON–(BUSINESS WIRE)–Silversmith Capital Partners (\u201cSilversmith\u201d) today announced the first and final close of its fourth fund, Silversmith Capital Partners IV (\u201cFund IV\u201d). Launched in May 2022, Fund IV was significantly oversubscribed and closed at its target and hard cap of $1.25 billion. In addition to the $1.25 billion from limited partners, the Silversmith team will … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46679","6":"format-standard","7":"category-industry"},"yoast_head":"\nSilversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON–(BUSINESS WIRE)–Silversmith Capital Partners (\u201cSilversmith\u201d) today announced the first and final close of its fourth fund, Silversmith Capital Partners IV (\u201cFund IV\u201d). Launched in May 2022, Fund IV was significantly oversubscribed and closed at its target and hard cap of $1.25 billion. In addition to the $1.25 billion from limited partners, the Silversmith team will ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-28T12:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220728005115\/en\/1526469\/21\/Silversmith_Partners.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Silversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund\",\"datePublished\":\"2022-07-28T12:01:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/\"},\"wordCount\":507,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005115\\\/en\\\/1526469\\\/21\\\/Silversmith_Partners.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/\",\"name\":\"Silversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005115\\\/en\\\/1526469\\\/21\\\/Silversmith_Partners.jpg\",\"datePublished\":\"2022-07-28T12:01:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005115\\\/en\\\/1526469\\\/21\\\/Silversmith_Partners.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220728005115\\\/en\\\/1526469\\\/21\\\/Silversmith_Partners.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/","og_locale":"en_US","og_type":"article","og_title":"Silversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund - Pharma Trend","og_description":"BOSTON–(BUSINESS WIRE)–Silversmith Capital Partners (\u201cSilversmith\u201d) today announced the first and final close of its fourth fund, Silversmith Capital Partners IV (\u201cFund IV\u201d). Launched in May 2022, Fund IV was significantly oversubscribed and closed at its target and hard cap of $1.25 billion. In addition to the $1.25 billion from limited partners, the Silversmith team will ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-28T12:01:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220728005115\/en\/1526469\/21\/Silversmith_Partners.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Silversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund","datePublished":"2022-07-28T12:01:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/"},"wordCount":507,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220728005115\/en\/1526469\/21\/Silversmith_Partners.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/","url":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/","name":"Silversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220728005115\/en\/1526469\/21\/Silversmith_Partners.jpg","datePublished":"2022-07-28T12:01:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220728005115\/en\/1526469\/21\/Silversmith_Partners.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220728005115\/en\/1526469\/21\/Silversmith_Partners.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/silversmith-capital-partners-raises-1-25-billion-for-fourth-growth-equity-fund\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Silversmith Capital Partners Raises $1.25 Billion for Fourth Growth Equity Fund"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46679"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46679\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}